AUROBINDO PHARMA
|
The Current P/E Ratio of AUROBINDO PHARMA is 22.93.
Share Price | ₹1,394.7 | Nov 06,2024 |
Market Cap | ₹81,001.3 Cr | |
Earnings-TTM | ₹3,533.2 Cr | TTM-Consolidated Results |
Price/Earnings | 22.93x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of AUROBINDO PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹81,001.3 Cr] as on Nov 06,2024
(/) Earnings [ ₹3,533.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 22.93x ]
Thus, for AUROBINDO PHARMA , the investors are currently willing to pay 22.93 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of AUROBINDO PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of AUROBINDO PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of AUROBINDO PHARMA
PE Ratio Performance Analysis for AUROBINDO PHARMA
- AUROBINDO PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 13.77x.
- AUROBINDO PHARMA 's operated at median p/e ratio of 14.8x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, AUROBINDO PHARMA 's p/e ratio peaked in Mar2024 at 20.12x.
- AUROBINDO PHARMA 's p/e ratio hit its five-year low in Mar2020 of 8.51x.
How does AUROBINDO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
AUROBINDO PHARMA | 3,533.22 | 22.93 | 81,001.3 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 39.37 | 438,418.0 |
CIPLA LTD | 4,485.22 | 28.71 | 128,755.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 20.11 | 108,720.0 |
ZYDUS LIFESCIENCES LTD | 4,181.90 | 23.94 | 100,120.0 |
DIVIS LABORATORIES LTD | 1,674.00 | 94.19 | 157,680.0 |
MANKIND PHARMA LTD | 2,124.86 | 51.85 | 110,181.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 60.28 | 108,624.0 |
LUPIN LTD | 2,287.78 | 43.17 | 98,759.4 |
ABBOTT INDIA LTD | 1,238.99 | 49.93 | 61,867.8 |
ALKEM LABORATORIES LTD | 2,073.89 | 33.74 | 69,979.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs AUROBINDO PHARMA 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 20.11x |
Max industry PE | 94.19x |
Median industry PE | 39.37x |
Average industry PE | 42.57x |
You may also like the below Video Courses